| Objective To observe the efficacy of autogenous cytokine-induced killer (CIK) cells on the life quality and immune status in the patients with advanced cancer.Methods From Feb 2013 to Mar 2016, 42 cases of patients with advanced cancer ever treated in our hospital were enrolled in the study, and according to their expected survival time, they were divided into group A of less than 3 months 20 cases and group B of equal to or more than 3 months 22 cases.All patients in the two groups were tested the levels of peripheral blood T lymphocyte subsets before and after the self-CIK cells treatment, and the changes of immune function and life quality in group A and group B before and after treatment, together with related adverse reactions, were observed.Results After treatment, the levels of CD3+ T lymphocytes in group A and CD8+ T lymphocytes in group B decreased significantly than before (all P<0.05), but the levels of CD3+, CD4+ and CD4+/CD8+ in group B increased significantly (P<0.05).The KPS scores after treatment in both groups were higher than those before treatment, but in group B the difference was significant (P<0.05), and in group A it was not (P>0.05).No remarkable adverse reaction was found during the infusion of self-CIK cells in these 42 patients.Conclusion The therapy of self-CIK cells transfusion is safe and low-toxic for the patients with advanced cancer, and might improve their immune function and life quality, but it should be carried out early. |
